Cognate BioServices announces acquisition of Cobra Biologics Transformative acquisition creates global cell and gene therapy manufacturing services platform for both...
Read More
Cognate BioServices Secures Growth Capital Investment from EW Healthcare to Continue to Expand Commercial Manufacturing Capacity and Services for the Cellular Therapies Industry ...
Read More
Caladrius Biosciences and Cognate BioServices Establish Manufacturing Agreement for Phase 3 Confirmatory Pivotal Clinical Trial of CLBS14 in No-option Refractory Disabling Angina ...
Read More
Memphis, June 10, 2019 – Cognate BioServices, Inc., a leading contract development and manufacturing organization (“CDMO”) in the global cellular therapies industry, today...
Read More
Memphis, TN & Menlo Park, CA. January 22nd, 2019 – Cognate BioServices, Inc., a leading contract development and manufacturing organization (“CDMO”) in the global cellular...
Read More
Memphis, TN September 28th, 2018 – Cognate BioServices, a leading contract development and manufacturing organization (“CDMO”) in the global cellular therapies industry, today...
Read More
Cognate BioServices and FloDesign Sonics Announce Collaboration to Advance Acoustic Cell Processing as a Platform for Cell Therapy Manufacturing Wilbraham, MA, September 4, 2018 –...
Read More
